Trajenta (linagliptin) has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk,.
Eli Lilly and Boehringer Ingelheim have announced top-line results from the CAROLINA cardiovascular outcome trial, which evaluated the cardiovascular safety of the drug compared to the sulphonylurea glimepiride, on top of standard of care in 6,033 adults with type II diabetes and increased cardiovascular risk or established cardiovascular disease.
With a median follow-up of more than six years, the trial adds evidence to the long-term safety profile of Trajenta in a broad range of adults with type II diabetes.
It also found that the overall safety profile of the treatment was consistent with previous data and no new safety signals were observed.
“Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit,” said Waheed Jamal, MD, corporate vice president and head of cardiovascular & metabolic medicine, Boehringer Ingelheim.
“When other therapies such as DPP-4 inhibitors are considered for people with type 2 diabetes, physicians need a treatment with an established long-term safety profile. With these results, CAROLINAexpands our understanding of the long-term cardiovascular safety of linagliptin, which now has one of the most comprehensive datasets on the cardiovascular safety of a DPP-4 inhibitor.”
The full data will be presented on 10 June at the American Diabetes Association’s 79th Scientific Sessions in San Francisco.
